燃石医学上涨8.51%，报6.153美元/股，总市值6624.47万美元

Core Viewpoint - On August 5, 2023, Burning Stone Medical (BNR) experienced an 8.51% increase in stock price, reaching $6.153 per share, with a total market capitalization of $66.2447 million [1] Financial Performance - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94% [1] - The company recorded a net profit attributable to shareholders of -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] Company Overview - Burning Stone Medical, established in 2014, focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company has a leading market share in tumor patient detection in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [2] - The company received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratories in Guangzhou, China, and California, USA, have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in testing [2] - The company aims to continue developing innovative and reliable NGS testing products to advance the field of precision oncology [2]